Sci Rep:甲基代谢中的异常甲基化关键基因是泌尿道上皮恶性肿瘤的分子病因学之一

2018-02-28 AlexYang MedSci原创

尿路上皮癌(UC)是泌尿膀胱癌中最为常见的癌症,可以引起严重的发病率和死亡率。在欧盟,大约每年有4万人因该病死亡,并且在医疗体系上,由于长久的治疗和长期的监控,能够产生巨大的花费。之前的研究表明,大量的异常的DNA甲基化在尿路上皮癌中十分流行,并且认为能够导致遗传的不稳定性。然而,该表观遗传改变在癌变过程中是怎样增加的仍旧不清楚。完整的甲基代谢在维持细胞类型特异性甲基化组上是需要的,从而保证遗传的

尿路上皮癌(UC)是泌尿膀胱癌中最为常见的癌症,可以引起严重的发病率和死亡率。在欧盟,大约每年有4万人因该病死亡,并且在医疗体系上,由于长久的治疗和长期的监控,能够产生巨大的花费。之前的研究表明,大量的异常的DNA甲基化在尿路上皮癌中十分流行,并且认为能够导致遗传的不稳定性。然而,该表观遗传改变在癌变过程中是怎样增加的仍旧不清楚。

完整的甲基代谢在维持细胞类型特异性甲基化组上是需要的,从而保证遗传的完整性和合适的细胞学功能。最近,有研究人员利用2个独立的技术来检测DNA甲基化,研究人员在早期尿路上皮恶性肿瘤中观察到了关键甲基化代谢基因ODC1、AHCY和MTHFR在5'调控区域过度甲基化。这些过度甲基化与遗传不稳定性相关。

最后,研究人员指出,甲基化代谢基因的过度甲基化在前馈循环中起作用,并且可以促进另外的一些甲基化改变,这些研究也表明了尿路上皮癌分子病因学的一个新的假设。

原始出处:

Lars Erichsen, Foued Ghanjati, Agnes Beermann et al. Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis. Sci Rep. 22 Feb 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986867, encodeId=0fce198686ec0, content=<a href='/topic/show?id=d92e301e1a2' target=_blank style='color:#2F92EE;'>#关键基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30171, encryptionId=d92e301e1a2, topicName=关键基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 17 11:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769122, encodeId=8b431e69122cb, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Fri Oct 05 15:15:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292022, encodeId=131d2920220b, content=不错.学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Thu Mar 01 16:48:40 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291786, encodeId=f8f1291e86ad, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Feb 28 21:19:28 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1986867, encodeId=0fce198686ec0, content=<a href='/topic/show?id=d92e301e1a2' target=_blank style='color:#2F92EE;'>#关键基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30171, encryptionId=d92e301e1a2, topicName=关键基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 17 11:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769122, encodeId=8b431e69122cb, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Fri Oct 05 15:15:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292022, encodeId=131d2920220b, content=不错.学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Thu Mar 01 16:48:40 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291786, encodeId=f8f1291e86ad, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Feb 28 21:19:28 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-10-05 lifestar
  3. [GetPortalCommentsPageByObjectIdResponse(id=1986867, encodeId=0fce198686ec0, content=<a href='/topic/show?id=d92e301e1a2' target=_blank style='color:#2F92EE;'>#关键基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30171, encryptionId=d92e301e1a2, topicName=关键基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 17 11:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769122, encodeId=8b431e69122cb, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Fri Oct 05 15:15:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292022, encodeId=131d2920220b, content=不错.学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Thu Mar 01 16:48:40 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291786, encodeId=f8f1291e86ad, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Feb 28 21:19:28 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-03-01 梦想起航ing

    不错.学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1986867, encodeId=0fce198686ec0, content=<a href='/topic/show?id=d92e301e1a2' target=_blank style='color:#2F92EE;'>#关键基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30171, encryptionId=d92e301e1a2, topicName=关键基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Thu Jan 17 11:15:00 CST 2019, time=2019-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769122, encodeId=8b431e69122cb, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Fri Oct 05 15:15:00 CST 2018, time=2018-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292022, encodeId=131d2920220b, content=不错.学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Thu Mar 01 16:48:40 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291786, encodeId=f8f1291e86ad, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Wed Feb 28 21:19:28 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 九九消寒

    优质资源.共同学习

    0

相关资讯

ASCO-GU 2018| 从IMmotion151研究看晚期肾癌未来一线治疗

2018年度ASCO GU公布了PD-L1单抗atezolizumab与贝伐珠单抗联合用于晚期肾癌一线治疗的Ⅲ期临床研究(IMmotion151),这是继去年ESMO大会公布ipilimumab(IPI)与PD-1单抗联合用于晚期肾癌一线治疗的Ⅲ期临床研究结果以来,第二项免疫治疗前移用于晚期肾癌一线治疗的大型临床研究,随着这两项Ⅲ期临床研究阳性结果的公布,晚期肾癌的一线治疗格局将被改写。

ASCO-GU 2018:晚期乳头状肾癌治疗进展

非透明细胞癌发病率低,约占所有肾癌的10%~15%,这其中主要以乳头状肾细胞癌为主。这些患者的治疗早期以手术为主,一旦出现转移,由于靶向药物的疗效普遍不如透明细胞癌,往往治疗比较棘手,近年来越来越受到重视,2018年ASCO GU会议上陆续公布了一些研究,值得临床参考与借鉴。

Sci Rep:血小板/淋巴细胞比例在泌尿肿瘤中的预后意义

在之前的研究中,血小板与淋巴细胞比例(PLR)和泌尿肿瘤生存之间的关系的研究结果并不一致。因此,最近,有研究人员进行了元分析来评估患有泌尿肿瘤的病人中PLR的预后意义。研究人员在PubMed、Embase和Web of Science数据库中进行了文献搜索,搜索的文献的时间到2017年7月,研究质量利用 Newcastle-Ottawa Scale评分系统进行分析。为了评估PLR和总生存(OS)和

上海建跨省泌尿肿瘤诊疗云平台,全国患者可实现远程会诊

经过一年多的筹备,一个会集中国多省市泌尿肿瘤领域医学“大咖”的云平台——中国泌尿肿瘤MDT(多学科综合诊治)平台在上海经测试后上线,这将造福全国广大患有前列腺癌、膀胱癌、肾癌等泌尿系统肿瘤的患者。不仅免去患者跑北上广看病就诊的尴尬难题,同时也让疑难病例的诊断经验实现全国共享,并可以被永久地纳入数据库,有机会让国内同行医生或医学院校生也能学习到治疗的先进理念和技术。这是记者从7月8日-7月9日在上海